Showing 2071-2080 of 18601 results for "".
Patient Perspectives on Subcutaneous vs IV Immunotherapies in Oncology Care
https://reachmd.com/programs/project-oncology/patient-perspectives-on-subcutaneous-vs-iv-immunotherapies-in-oncology-care/36402/How do real-world patients experience subcutaneous versus IV immunotherapies? That’s exactly what a first-of-its-kind U.S. study set out to uncover. Tune in to this Audio Abstract to hear the key findings published in Oncology and Therapy and how they could reshape patient-centered cancer care. RefeOptimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
https://reachmd.com/programs/project-oncology/optimizing-nivolumab-in-nsclc-implications-for-cost-access-and-outcomes/32997/Emerging evidence suggests that combining low-dose nivolumab and chemotherapy in the neoadjuvant setting may retain immunologic efficacy while drastically lowering cost and toxicity for non-small cell lung cancer (NSCLC) patients. Additionally, this approach could help optimize trial design with dosCOVID-19 Recovery: Investigating the Link Between Inflammation and Cognitive Symptoms
https://reachmd.com/programs/clinicians-roundtable/covid-19-recovery-investigating-the-link-between-inflammation-and-cognitive-symptoms/35465/A post hoc analysis of the CONTAIN randomized clinical trial tracked inflammatory markers and health outcomes up to 18 months post-hospitalization. Based on the results, markers like cytokines, D-dimer, and fibrinogen declined over time, and no clear link was found between persistent inflammation anEvaluating the Safety of Ixekizumab in Psoriasis and Arthritis Patients
https://reachmd.com/programs/clinicians-roundtable/evaluating-the-safety-of-ixekizumab-in-psoriasis-and-arthritis-patients/32447/Learn about the risk of adverse events associated with ixekizumab in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis.Dupilumab's Impact on Height, 40-GEP for HNcSCC Lead Posters at Maui Derm
https://reachmd.com/programs/practical-dermatology/dupilumabs-impact-on-height-40-gep-for-hncscc-lead-posters-at-maui-derm/32916/The impact of dupilumab on children’s height and the 40-gene expression profile (40-GEP) test for patients with cutaneous squamous cell carcinoma of the head and neck (HNcSCC) were the topics of the top two posters in the “Late Breakers 2025” session at Maui Derm 2025 in Maui, Hawaii.The BALTAZAR Study: How Caffeine Intake Affects Alzheimer's Biomarkers
https://reachmd.com/programs/neurofrontiers/the-baltazar-study-how-caffeine-intake-affects-alzheimers-biomarkers/29092/Here’s how daily caffeine intake could benefit cognitive functioning, particularly in patients with Alzheimer’s disease or mild cognitive impairment.The Critical Importance of Flu Vaccination: A Patient Advocate’s Story
https://reachmd.com/programs/vaccination/the-critical-importance-of-flu-vaccination-a-patient-advocates-story/26598/A patient advocate shares her family’s tragic story so we can better understand the seriousness of influenza and the importance of vaccination.Overcoming Controversies of Irritable Bowel Syndrome
https://reachmd.com/programs/gi-insights/overcoming-controversies-of-irritable-bowel-syndrome/18100/Dive in to learn about solutions to controversies surrounding IBS.GI Around the World: A Look at IBS in Asia
https://reachmd.com/programs/gi-insights/gi-around-the-world-a-look-at-ibs-in-asia/13807/Since IBS varies by geography, culture, and environment, join us as we take a look at IBS in the Asian population.Impact of New First-in-Class Medical Therapy in Obstructive HCM
https://reachmd.com/programs/acc-action-center/impact-of-new-first-in-class-medical-therapy-in-obstructive-hcm/13776/How might the VALOR-HCM trial impact the treatment of obstructive hypertrophic cardiomyopathy? Find out with this recap of a session from ACC 2022.